Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
Status
RECRUITING
Phase
NA
Age
30 - 85 Years
Enrollments
50Conditions
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8Summary
This clinical trial evaluates the use of an imaging scan (18F-rhPSMA-7.3 positron emission tomography [PET]/magnetic resonance imaging [MRI]) for identifying patients who are at risk of having their disease spread to the lymph nodes in those undergoing radical prostatectomy for prostate cancer that has not spread to other parts of the body (localized). Prostate specific membrane antigen (PSMA) PET/computed tomography (CT) has emerged as an option to stage newly diagnosed high risk prostate cancer patients. PSMA PET/CT has demonstrated improved diagnostic accuracy for identifying metastasis. PET is procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is used. Because cancer cells often use more glucose than normal cells, the pictures can be used to find cancer cells in the body. MRI is procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. These pictures can show the difference between normal and diseased tissue. This study may help researchers learn whether 18F-rhPSMA-7.3 PET/ MRI may improve predicting which patients are at risk of lymph node metastases and who are suitable candidates for pelvic lymph node dissection in patients with localized high-risk prostate cancer undergoing radical prostatectomy.
Detailed Description
PRIMARY OBJECTIVE:
I. To investigate the diagnostic ability of flotufolastat F-18 gallium (18F-rhPSMA-7.3) PSMA PET/MRI prior to radical prostatectomy in newly diagnosed, high-risk prostate cancer patients.
SECONDARY OBJECTIVES:
I. Calculating the specificity, positive-predictive value, and negative-predictive value for the detection of lymph node positivity.
II. Investigating the rates of biochemical recurrence (BCR) as measured by post-operative prostate specific antigen (PSA) (PSA > 0.20) at pre-defined timepoints in patients.
OUTLINE:
Patients receive 18F-rhPSMA-7.3 intravenously (IV) and undergo PET/MRI up to 30 days prior to standard of care (SOC) robotic radical prostatectomy with bilateral pelvic lymph node dissection. Patients also undergo CT or MRI, bone scan and tissue collection during screening.
Upon completion of study treatment, patients are followed up at 6 weeks, 3 months, 9 months, and 12 months post-surgery.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Clinical Trials Referral Office
- 855-776-0015
- [email protected]
Principal Investigator
- Ram A. Pathak, M.D.
Eligibility Criteria
Inclusion Criteria:
* Male subjects with at least age 30 to 85
* Primary diagnosis of prostate cancer selected for surgical intervention (radical prostatectomy with extended lymph node dissection)
* Primary diagnosis of untreated American Urological Association (AUA) guidelines high-risk localized prostate cancer, hormone-naïve prostate cancer via contrast enhanced prostate MRI + tissue sampling
* Planned elective radical prostatectomy with extended pelvic lymph node dissection
* Clinical oligometastatic disease with < 3 nodes positive on 18F-rhPSMA-7.3 PSMA
* Patient has the willingness to comply with instruction of the investigator
* Patient has the willingness to comply with follow-up surveillance
* Have ability to provide full written consent
Exclusion Criteria:
* High-risk cancer planned for neoadjuvant therapy
* Patients with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study
* Patients that have had prior hormonal therapy such as Lupron or oral antiandrogens
* Clinical oligometastatic disease with > 3 nodes positive on 18F-rhPSMA-7.3 PSMA
* Previous history of pelvic radiation
* Patients with obesity defined as body mass index (BMI) > 40 kg/m^2
* History of prior mesh for inguinal hernia repair
* Scheduled at the time of screening to undergo chemotherapy, radiation, hormone therapy, or open surgery during the study period
* Inability to lie still for 75 minutes during 18F-rhPSMA-7.3 PSMA PET-MRI imaging
* Any neurologic disorder or psychiatric disorder that might confound postsurgical assessments
* Has any condition(s), which seriously compromises the subject's ability to participate in this study, sign consent, or has a known history of poor adherence with medical treatment
* Received administration of an investigational drug within 30 days prior to study, and/or has planned administration of another investigational product or procedure during participation in this study
Study Plan
Screening (18F-rhPSMA-7.3 PET/MRI)
EXPERIMENTAL
Patients receive 18F-rhPSMA-7.3 IV and undergo PET/MRI up to 30 days prior to SOC robotic radical prostatectomy with bilateral pelvic lymph node dissection. Patients also undergo CT or MRI, bone scan and tissue collection during screening.
PROCEDURE:
Bilateral Pelvic Lymph Node DissectionDescription:
Undergo bilateral pelvic lymph node dissectionPROCEDURE:
Biospecimen CollectionDescription:
Undergo tissue sample collectionPROCEDURE:
Bone ScanDescription:
Undergo bone scanPROCEDURE:
Computed TomographyDescription:
Undergo CTOTHER:
Electronic Health Record ReviewDescription:
Ancillary studiesOTHER:
Flotufolastat F-18 GalliumDescription:
Given IVPROCEDURE:
Laparoscopic Radical Prostatectomy with RoboticsDescription:
Undergo robotic radical prostatectomyPROCEDURE:
Magnetic Resonance ImagingDescription:
Undergo MRI or PET/MRIPROCEDURE:
Positron Emission TomographyDescription:
Undergo PET/MRI
Outcome Measures
Primary Outcome Measures
Sensitivity of flotufolastat F-18 gallium (18F-rhPSMA-7.3) positron emission tomography (PET)/magnetic resonance (MRI) for the detection of lymph node metastasis
Secondary Outcome Measures
Specificity
Positive/negative predictive value
Prostate specific antigen (PSA): < 5, 5-10, 10-20, > 20
Gleason score
Digital rectal examination
Number of patients where management has changed
Rates of biochemical recurrent disease (BCR)
Timeline
Last Updated
June 13, 2024Start Date
April 29, 2024Today
January 16, 2025Completion Date ( Estimated )
May 1, 2026
Sponsors of this trial
Lead Sponsor
Mayo Clinic
RECRUITING 
21 - 64 Years